01.10.23 -- End-To-End Development And Manufacturing: Small Volume Commercial Products

To meet ambitious orphan drug development timelines, CDMOs must be able to scale quickly to progress from early clinical development to validation and commercial launch.

Explore the importance of fate and purge studies, which measure the ability of the process to remove impurities and provide evidence of their removal.

Choosing the right tag is essential to getting the purity, solubility, and protein quality your application needs. Learn how to prepare a recombinant protein in the quantity and quality you need.

Discover an approach to wastewater treatment that reduces the environmental impact of small molecules production and introduces advanced treatment methodologies to avoid wastewater incineration.

The pros and cons of soluble and insoluble processes: isolating, solubilizing, and properly refolding, and strategies to improve the performance of IB processes.